文献速递湿疹皮炎与荨麻疹

巴瑞替尼联合外用糖皮质激素对中重度特应性皮炎患者症状、生活质量及功能的影响:BREEZE-AD7 III期随机试验

Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2021-06-05

BREEZE-AD7是一项III期双盲随机对照试验,纳入329例对TCS应答不足的中重度AD成人患者,按1:1:1随机接受安慰剂、巴瑞替尼4mg或2mg联合TCS治疗。结果显示,巴瑞替尼联合TCS较安慰剂联合TCS在第2周即显著改善DLQI≥4分应答,并快速改善WPAI-AD出勤主义损害和PROMIS瘙痒干扰,4mg组疗效持续至第16周;第16周PBI全局评分也显著改善。

要点

  • 巴瑞替尼4mg或2mg联合TCS较安慰剂联合TCS在第2周即显著改善DLQI≥4分应答。
  • 巴瑞替尼联合TCS在第1周显著改善WPAI-AD出勤主义损害,第2周改善PROMIS瘙痒干扰。
  • 4mg组疗效持续至第16周,第16周PBI全局评分显著优于安慰剂联合TCS。

核心结论

  • 巴瑞替尼联合TCS较安慰剂联合TCS在第16周显著改善治疗获益,并在16周内快速显著改善HRQoL及AD症状对工作效率和功能的影响。

研究设计与样本

  • BREEZE-AD7是一项III期、多中心、双盲随机对照试验,共随机329例中重度AD成人患者。
  • 患者按1:1:1随机接受每日口服安慰剂、巴瑞替尼4mg或2mg,均联合背景TCS治疗。
  • 主要使用DLQI、WPAI-AD、PROMIS瘙痒与睡眠量表及PBI等患者报告结局(PRO)从第1周评估至第16周。
  • 数据采用逻辑回归(分类变量)和混合模型重复测量(连续变量)分析,PBI评分采用方差分析。

主要发现

  • 巴瑞替尼4mg联合TCS组(N=111)和2mg联合TCS组(N=109)较安慰剂联合TCS组(N=109)在第2周即出现DLQI≥4分改善的快速显著差异(4mg组P≤0.001;2mg组P≤0.05)。
  • WPAI-AD出勤主义损害自基线变化在第1周即显著改善(4mg组P≤0.01;2mg组P≤0.05)。
  • PROMIS瘙痒干扰在第2周显著改善(4mg组P≤0.01)。
  • 4mg联合TCS组的改善持续至第16周。
  • 第16周PBI全局评分显著改善(4mg组P≤0.001;2mg组P≤0.05)。

关键数值与推荐

  • DLQI≥4分改善:第2周4mg联合TCS组P≤0.001,2mg联合TCS组P≤0.05(对比安慰剂联合TCS)。
  • WPAI-AD出勤主义损害自基线变化:第1周4mg联合TCS组P≤0.01,2mg联合TCS组P≤0.05。
  • PROMIS瘙痒干扰:第2周4mg联合TCS组P≤0.01。
  • PBI全局评分:第16周4mg联合TCS组P≤0.001,2mg联合TCS组P≤0.05。

临床怎么用

  • 对于对TCS应答不足的中重度AD成人患者,巴瑞替尼联合TCS可快速改善生活质量、工作效率及瘙痒干扰。
  • 巴瑞替尼4mg联合TCS的疗效在16周内持续,2mg联合TCS亦显示早期获益。
  • 临床评估应结合DLQI、WPAI-AD、PROMIS瘙痒及PBI等患者报告结局综合判断治疗获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Baricitinib is an oral, selective, reversible Janus kinase 1/2 inhibitor approved in the European Union and Japan and under investigation in the United States for treatment of atopic dermatitis (AD). OBJECTIVES: To evaluate the impact of baricitinib plus background topical corticosteroids (TCS) on health-related quality of life (HRQoL), how AD symptoms impact work productivity and life functioning, and treatment benefit using patient-reported outcome (PRO) assessments in patients with moderate-to-severe AD previously experiencing inadequate response to TCS. METHODS: Adult patients with AD in BREEZE-AD7, a Phase 3, multicentre, double-blind trial, were randomised 1 : 1 : 1 to daily oral placebo (control) or baricitinib 4- or 2-mg plus TCS. PROs reported Week 1 through Week 16: Dermatology Life Quality Index (DLQI), Work Productivity and Activity Impairment-AD (WPAI-AD); Patient-Reported Outcomes Measurement Information System (PROMIS) Itch and Sleep measures, and Patient Benefit Index (PBI). Data were analysed using logistic regression (categorical) and mixed model repeated measures (continuous). PBI scores were analysed using analysis of variance. RESULTS: A total of 329 patients were randomised. Treatment with baricitinib 4-mg (N = 111) or 2 mg (N = 109) plus TCS led to rapid, statistically significant improvements [vs. TCS plus placebo (N = 109)] in DLQI ≥4-point improvement starting at Week 2 (4-mg plus TCS, P ≤ 0.001; 2-mg plus TCS P ≤ 0.05), change from baseline in WPAI-AD presenteeism at Week 1 (4-mg plus TCS, P ≤ 0.01; 2-mg plus TCS P ≤ 0.05) and PROMIS itch interference at Week 2 (4-mg plus TCS P ≤ 0.01). Improvements were sustained through Week 16 for baricitinib 4-mg. Statistically significant improvements were observed at Week 16 for PBI global score (4-mg plus TCS, P ≤ 0.001; 2-mg plus TCS P ≤ 0.05). CONCLUSIONS: Baricitinib plus TCS vs. placebo plus TCS showed significant improvements in treatment benefit at Week 16 and rapid significant improvements in HRQoL and impact of AD symptoms on work productivity and functioning through 16 weeks.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Wollenberg A, Nakahara T, Maari C, et al. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial. J Eur Acad Dermatol Venereol. 2021. PMID: 33834521. doi:10.1111/jdv.17278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。